Related Experiment Video
Updated: Aug 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Autoimmune cardiolipin-binding antibodies in oral anticoagulant patients
Insights
Elevated anticardiolipin antibody (ACA) levels were found in 14% of patients on warfarin therapy. Raised ACA may indicate an acquired prothrombotic state, particularly in younger patients with thromboses.
Area of Science:
- Immunology
- Hematology
Background:
- Oral anticoagulant therapy, such as warfarin, is common for managing thrombotic conditions.
- Anticardiolipin antibodies (ACA) are associated with thrombophilia, but their prevalence in patients on anticoagulation requires further investigation.
Purpose of the Study:
- To determine the prevalence and significance of elevated anticardiolipin antibody (ACA) levels in patients undergoing routine oral anticoagulant therapy.
- To explore potential associations between raised ACA and patient demographics, clinical indications for anticoagulation, and autoimmune markers.
Main Methods:
- A well-standardized enzyme-linked immunosorbent assay (ELISA) was used to assess ACA levels in 140 patients on warfarin.
- Patients were categorized based on their treatment indication (thrombotic episodes vs. heart valve replacement).
- Additional autoimmune markers, including antinuclear antibodies (ANA) and lupus anticoagulant, were evaluated in a subset of patients.
Main Results:
- 14% of patients on warfarin therapy exhibited elevated ACA levels ( > 4 SD above normal).
- A higher incidence of raised ACA was observed in patients treated for thrombotic episodes (19%) compared to those with heart valve replacements (11%).
- The highest ACA titers were noted in younger patients with thromboses on short-term anticoagulation; autoimmune etiology was suggested in a minority.
Conclusions:
- Elevated ACA is a significant finding in patients on oral anticoagulant therapy.
- Raised ACA may serve as a marker for an acquired prothrombotic state, warranting further clinical consideration.
- ACA did not appear to negatively impact patient conditions during anticoagulant therapy.
Abstract:
In a routine clinic of patients taking regular oral anticoagulant therapy (warfarin, n = 140) 14% were found to have elevated levels (greater than 4 SD above normal) of anticardiolipin antibody (ACA) assessed by a well standardised enzyme linked immunosorbent assay (ELISA). There was a higher incidence of raised ACA in patients being treated for thrombotic episodes (9/47 = 19%) than in cases with heart valve replacements (8/75 = 11%). Furthermore, the highest ACA titres were in younger patients with thromboses scheduled for short-term anticoagulant treatment. Borderline DNA binding studies, together with some positive ANA results, suggested autoimmune etiology in the minority of these cases. Lupus anticoagulant was strongly detectable in only one such patient. The ACA were predominantly IgG (14/17) and did not appear to compromise the conditions of patients while on anticoagulant therapy. Raised ACA may be a highly significant marker for an acquired prothrombotic state.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Myocarditis II: Clinical Features and Diagnostic Tests

